

Innovative Medicines Initiative 2 Funding opportunities in 2020

The **Innovative Medicines Initiative (IMI)** has now launched its **20th Call for proposals under IMI2**. The Call gives researchers from diverse sectors the opportunity to participate in **ambitious public-private partnerships** that will pave the way for the development of the **medicines of the future**.

Why apply?

- Obtain **research funding**
- Take part in **scientifically excellent, patient-centric** research
- Join unique consortia involving **top teams** from industry, academia, SMEs, regulators, and others
- Benefit from the **expertise, databases, and infrastructures** of consortium partners
- Boost the **visibility and status** of your organisation in Europe and globally and gain **access to new markets**

IMI2 – Call 20

IMI2 – Call 20 was launched on 21 January 2020 and is a standard, two-stage Call for proposals. It includes the following topics:

- Early diagnosis, prediction of radiographic outcomes and development of rational, personalised treatment strategies to improve long-term outcomes in **psoriatic arthritis**
- Innovations to accelerate **vaccine development and manufacture**
- Academia and industry united innovation and treatment for **tuberculosis** (UNITE4TB)
- **Tumour** plasticity
- Proton versus photon therapy for **oesophageal cancer** – a trimodality strategy
- Handling of **protein drug products** and stability concerns

Read the topic texts:

bit.ly/imi2call20

Sign up for the webinars:

bit.ly/2S39Eob

Deadline for short proposals:

21 April 2020

How to apply

- The rules and details of how to apply can be found via the Call pages of the IMI website.
- Follow IMI's tips for applicants – see bit.ly/IMItips
- Get advice on finding project partners on our partner search page – bit.ly/IMIfindpartners

Future IMI Calls for proposals

The following topics are under consideration for inclusion in future IMI Calls for proposals in the longer term. Discussions on these topics are still in their early stages, so topics may change considerably and they will probably not be ready for inclusion in an IMI Call for several months. Furthermore, as the discussions advance, it is likely that some topics will be added to this list while others will be dropped. In any case, we hope that this list will give potential applicants a useful glimpse into what is under development in the longer term, and provide additional time to enhance their network. We will update this list whenever we have updates on the status of the topics. Summaries of the topics can be found in [this document](#).

Neurodegeneration and other neuroscience priorities	Rare neurodegenerative and neurocognitive diseases clinical platform development Complement in neurodegenerative diseases
Infection control including vaccines	Development of innovative personalized diagnostics and patient-guided therapies for the management of sepsis-induced immune suppression Modelling the impact of monoclonal antibodies and vaccines on the reduction of antimicrobial resistance
Big data, digital health, clinical trials and regulatory research	Data lakes Personalised endpoints Returning clinical trial data to patients
Oncology	Real-world clinical implementation of liquid biopsy Microbiome
Translational safety	Pharmacodynamic drug-drug interaction predictive testing by learning algorithms to enhance safety Digital vivarium
Facilitating rare disease therapies (including Advanced Therapy Medical Products) reaching patients in Europe	Clinical outcomes assessments for rare diseases Defragmenting and shortening the path to rare disease diagnosis by using genetic screening and digital technologies
Restricted Call to maximise the impact of IMI2 JU objectives and scientific priorities	

About the Innovative Medicines Initiative

At IMI, we are working to improve health by speeding up the development of, and patient access to, innovative medicines, particularly in areas where there is an unmet medical or social need. We do this by facilitating collaboration between the key players involved in healthcare research.

We are a partnership between the European Union and the European pharmaceutical industry (represented by EFPIA, the European Federation of Pharmaceutical Industries and Associations), and have a €3.3 billion budget for the period 2014-2020.

Since our launch in 2008, we have launched over 125 projects in areas as diverse as dementia, pain, diabetes, autoimmune disease and antimicrobial resistance as well as tools for drug discovery and development, clinical trial design, and drug and vaccine safety.

Stay in touch

Visit the IMI website:
www.imi.europa.eu

Sign up to the IMI Newsletter:
bit.ly/IMINewsletter

Follow us on Twitter:
[@IMI_JU](https://twitter.com/IMI_JU)

Join the IMI group on LinkedIn:
bit.ly/LinkedInIMI

E-mail us:
infodesk@imi.europa.eu

Get support:
bit.ly/IMIsupport